HB002.1M

HB002.1M is a first-in-class recombinant human vascular endothelial growth factor (VEGF) receptor-antibody fusion protein developed for ophthalmic use. It acts as an antagonist of VEGF by binding to and inhibiting VEGF activity, thereby reducing abnormal blood vessel formation and vascular permeability associated with retinal diseases. The drug is being developed primarily for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), branch retinal vein occlusion secondary to macular edema, and central retinal vein occlusion secondary to macular edema[1][2][3]. The developer is Huabo Biopharm, a subsidiary of Shanghai Huaaotai Biopharmaceutical Co., Ltd.[3]. As of April 2022, the highest development phase reached by HB002.1M is Phase II clinical trials in China for both wet AMD and DME[1].

Other names

Recombinant human vascular endothelial growth factor receptor-immunoglobulin Fc fusion protein